Abstract
This study assesses how a limited supply of monoclonal antibody therapy was allocated to patients at highest risk of severe disease among a population of fee-for-service Medicare beneficiaries with a new COVID-19 diagnosis or confirmed exposure between November 2020 and August 2021.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have